Research on medical equipment and medical service industry: high-end medical care is setting sail, domestic equipment is at an inflection point
2022-02-17
In 2022, we will continue to be optimistic about the three main lines of "import substitution of scientific research reagents, domestic high-end medical equipment ushering in an inflection point, and medical consumption upgrade"
1) Q1-3 performance review of medical devices and services in 2020 and 2021:
According to the classification of Shenwan Pharmaceutical, the medical device segment will achieve an operating income of 197.196 billion yuan in 2020, a year-on-year increase of 67.35%; in 21Q1-3, an operating income of 188.362 billion yuan, a year-on-year increase of 35.76%, the growth rate has declined compared with 2020; the medical service segment In 2020, the operating income was 74.463 billion yuan, a year-on-year increase of 15.22%; in 21Q1-3, the operating income was 75.205 billion yuan, a year-on-year increase of 46.03%, and the growth rate was significantly higher than that in 2020.
As for medical device companies, under the COVID-19 epidemic in 2020, diagnostic companies such as Orient Bio, Wanfu Bio, Shengxiang Bio, BGI, etc. have brought about rapid growth in performance through the domestic and overseas sales of related COVID-19 diagnostic reagents. Equipment companies such as Mindray Medical, Yuyue Medical, etc. through the domestic and overseas sales of ventilators, monitors and other products have also brought about a significant increase in revenue, and starting from the second quarter of 2021, with the increase in vaccination rates, domestic and foreign epidemics have eased, and medical equipment The sales of the company's anti-epidemic products began to slow down, and the growth rate of revenue declined significantly under the high base in the same period last year. Before that, some companies with elective diagnosis or surgery were hit by the epidemic. After the epidemic eased, they gradually began to recover. It is expected that the growth rate of non-anti-epidemic medical device products will gradually recover.
In terms of medical service companies, after the outbreak of the new crown epidemic in 2020, most parts of the country adopted strict home isolation measures, resulting in the suspension of outpatient clinics in hospitals, and the number of outpatient clinics dropped significantly, especially for departments such as stomatology and ophthalmology that can be treated selectively. Based on this In 2020, medical service enterprises will show a trend of slowing revenue growth as a whole. With the gradual improvement of the domestic epidemic, the performance of medical service enterprises will gradually show a recovery trend in the second half of 2020 and 2021. Q1-3 in 2021 Faster growth from a low base.
2) Review of industry situation and major policies:
China's medical device industry market is growing rapidly, and the post-epidemic era is expected to usher in new opportunities. China is the world's second largest medical device market. Since 2020, the new crown epidemic has struck. In this struggle to prevent and control the new crown pneumonia epidemic, the medical device industry has timely provided a large number of diagnostic reagents, ventilators, protective clothing, various Protective equipment such as protective masks has played an irreplaceable role. The State Drug Administration has continuously deepened the reform of medical device review and approval, optimized the review and approval process, continuously improved the efficiency of review and approval, and accelerated the emergence of innovative medical device products. Looking ahead, our medical device industry is still in a "golden development period" with broad prospects.
The national policy strongly supports the restriction of domestic medical equipment and imported products, and the domestic equipment is expected to usher in the hospital's benefits. On June 21, 2021, the Guangdong Provincial Drug Administration issued the "Interim Regulations on the Administration of Imported Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area of Guangdong Province (Draft)". The draft proposes that even for urgent clinical needs, there are only three special Only in certain circumstances can you choose to import: (1) those that have not been approved for registration in mainland China; (2) those that are irreplaceable by registered products; (3) those that have been purchased by the hospital, are urgently needed clinically, and have advanced clinical applications. After the application is submitted, it needs expert verification and is only valid for one year. Once the product is recalled overseas, it must be discontinued in China. A series of measures reflect the careful application of imported products and support for domestic products.
In October 2021, the Ministry of Finance and the Ministry of Industry and Information Technology jointly issued the "Guidelines for the Review of Government Procurement of Imported Products" (2021 version), which clearly stipulated the proportion requirements for government agencies (institutions) to purchase domestically produced medical devices and instruments, of which 137 are All medical devices require 100% domestic purchases; 12 types of medical devices require 75% domestic purchases; 24 types of medical devices require 50% domestic purchases; 5 types of medical devices require 25% domestic purchases. On this basis, domestic medical equipment configuration is expected to usher in Admission to the hospital is good.
3) The main investment strategies and directions in the future: We are optimistic about the three main lines of "substitution of imported scientific research reagents, the turning point of domestic high-end medical equipment, and the upgrading of medical consumption". 1) For the scientific research reagent industry, we believe that it is one of the few high-quality tracks in the entire pharmaceutical sector that has the advantages of “large industry space for growth, accelerated import substitution, and relatively immune policies”. Enterprises and products already have the strength to compete with foreign capital, and import substitution is an inevitable trend. 2) For high-end medical equipment companies, endoscopes and other high-end equipment have the characteristics of high technical barriers and late start in China. The representative domestic enterprises with strong R&D capabilities, we believe that under the industry background of new medical infrastructure and the government's strong support for domestic equipment, domestic high-end medical equipment enterprises are expected to achieve corner overtaking. 3) For medical consumer companies, optional consumer terminals are relatively less affected by policy suppression, and the trend of aging and per capita disposable income is expected to bring about a rapid increase in industry demand.
Contact Info
Address: No. 1668 Huacheng Road, Jintan District, Changzhou city, Jiangsu Province
Phone: 86-519-82982668
Mobile: 86-18118332098
E-mail: 503472568@qq.com
Website
Copyright© 2022 Jiangsu Longtaifeng Medical Equipment Co., Ltd. Powered by www.300.cn
This site supports IPV6 SEO